TY - JOUR
T1 - Epoprostenol Therapy Decreases Elevated Circulating Levels of Monocyte Chemoattractant Protein-1 in Patients with Primary Pulmonary Hypertension
AU - Hashimoto, Katsushi
AU - Nakamura, Kazufumi
AU - Fujio, Hideki
AU - Miyaji, Katsumasa
AU - Morita, Hiroshi
AU - Kusano, Kengo
AU - Date, Hiroshi
AU - Shimizu, Nobuyoshi
AU - Emori, Tetsuro
AU - Matsubara, Hiromi
AU - Ohe, Tohru
PY - 2004/3
Y1 - 2004/3
N2 - Background: Primary pulmonary hypertension (PPH) is a rare disease characterized by progressively increased resistance of the pulmonary arteries associated with vascular remodeling. Infiltration of inflammatory cells in affected vessels is a common pathological finding. Monocyte chemoattractant protein-1 (MCP-1) is recognized as a potent chemotactic and activating factor for monocytes and leukocytes, but its significance in PPH is unclear. Methods and Results: Serum MCP-1 concentrations were measured in 16 PPH patients and the results were compared with those in 16 normal controls. MCP-1 concentrations in PPH patients (265.6±29.5 pg/ml) were significantly elevated compared with those in normal controls (119.6±6.9 pg/ml, p<0.0001). In 9 patients (3 men, 6 women; mean age, 29±3 years), repeated MCP-1 and hemodynamic measurements were performed prior to and during intravenous epoprostenol therapy. During a mean follow-up period of 7±1 months, MCP-1 concentrations were significantly reduced (288.8±122.8 to 185.9±117.5 pg/ml, p<0.01). Conclusion: Circulating MCP-1 concentrations are increased in PPH patients, but can alleviated by chronic intravenous epoprostenol therapy. The increase in MCP-1 might be one of the important factors responsible for the disease development in patients with PPH.
AB - Background: Primary pulmonary hypertension (PPH) is a rare disease characterized by progressively increased resistance of the pulmonary arteries associated with vascular remodeling. Infiltration of inflammatory cells in affected vessels is a common pathological finding. Monocyte chemoattractant protein-1 (MCP-1) is recognized as a potent chemotactic and activating factor for monocytes and leukocytes, but its significance in PPH is unclear. Methods and Results: Serum MCP-1 concentrations were measured in 16 PPH patients and the results were compared with those in 16 normal controls. MCP-1 concentrations in PPH patients (265.6±29.5 pg/ml) were significantly elevated compared with those in normal controls (119.6±6.9 pg/ml, p<0.0001). In 9 patients (3 men, 6 women; mean age, 29±3 years), repeated MCP-1 and hemodynamic measurements were performed prior to and during intravenous epoprostenol therapy. During a mean follow-up period of 7±1 months, MCP-1 concentrations were significantly reduced (288.8±122.8 to 185.9±117.5 pg/ml, p<0.01). Conclusion: Circulating MCP-1 concentrations are increased in PPH patients, but can alleviated by chronic intravenous epoprostenol therapy. The increase in MCP-1 might be one of the important factors responsible for the disease development in patients with PPH.
KW - Epoprostenol
KW - Monocyte chemoattractant protein-1
KW - Pulmonary hypertension
UR - http://www.scopus.com/inward/record.url?scp=12144290664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12144290664&partnerID=8YFLogxK
U2 - 10.1253/circj.68.227
DO - 10.1253/circj.68.227
M3 - Article
C2 - 14993777
AN - SCOPUS:12144290664
VL - 68
SP - 227
EP - 231
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 3
ER -